Atopic dermatitis (AD) is a common yet complex skin disease, posing a therapeutic
challenge with increasingly recognized different phenotypes among variable patient …

abstract Atopic dermatitis (AD) is a heterogenous disorder and can be classified into
different types. Stratification of subtypes may enable personalized medicine approaches. AD …

Background Tralokinumab, a fully human monoclonal antibody, specifically neutralizes
interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …

Background Atopic dermatitis (AD) is a prevalent inflammatory skin disease with a complex
pathogenesis involving immune cell and epidermal abnormalities. Despite whole tissue …

Recent research advancements indicate that atopic dermatitis (AD) is a complex disease
characterized by different subtypes/phenotypes based on age, disease chronicity, ethnicity …

Over the past two decades, significant progress in understanding of the pathogenesis of type
2 chronic inflammatory diseases has enabled the identification of compounds for more than …

Background Our current understanding of atopic dermatitis (AD) and psoriasis
pathophysiology is largely derived from skin biopsy studies that cause scarring and may be …

Background Previous studies showed the potential effectiveness of delgocitinib ointment, a
novel topical Janus kinase inhibitor, in atopic dermatitis (AD). Objective This study aimed to …

Background Baricitinib, an oral selective Janus kinase 1/Janus kinase 2 inhibitor, is being
studied for moderate-to-severe atopic dermatitis (AD) in adults. Objective To evaluate the …

Atopic dermatitis (AD) is a common inflammatory skin disease characterized by intense
pruritus and recurrent eczematous lesions that significantly impair quality of life. It is a …